Orca-T May Make Transplants Safer, More Effective in Hematologic Cancers

In a conversation with CancerNetwork^®, Wendy Stock, MD, discussed what the potential FDA approval of Orca-T would mean for different hematologic malignancy populations. Specifically, she emphasized the “exciting possibility” that Orca-T may make allogeneic transplants safer and more effective procedures for patients.

Stock, Anjuli Seth Nayak Professor of Medicine, co-chair of the Leukemia Committee for the National Cancer Institute-supported Alliance for Clinical Trials in Oncology, and a co-leader of the Clinical and Experimental Therapeutics research program at the University of Chicago Medicine Comprehensive Cancer Center, highlighted Orca-T’s potential ability to modulate graft-versus-host disease among patients undergoing transplantation. These properties may, in turn, facilitate quicker immune reconstitution for patients with different hematologic malignancies.

The FDA granted priority review to Orca-T as a treatment for patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome in October 2025.¹ Following the submission of additional chemistry, manufacturing, and controls data as part of the standard review process, the FDA extended the review period for Orca-T in April 2026, adjusting the Prescription Drug User Fee Act date to July 6, 2026.²

Transcript:

The potential approval of [Orca-T] is quite exciting in the sense that it will hopefully allow patients to [experience] better outcomes after allogeneic transplant for these disorders. The hope is that the allogeneic transplant is a potentially curative procedure for these malignancies. Making it safer and potentially even more effective is something that we all strive for on a daily basis. This is an exciting possibility.

Orca-T is a cellular therapy product. What the goal of the Orca-T product is that [when] you're infusing these regulatory T cells, that will modulate graft-versus-host disease and potentially allow for quicker immune reconstitution in patients undergoing allogeneic transplant. This is an approach that has never been used before in the setting of [allogeneic] transplant for the prevention of graft-versus-host disease. It's quite exciting that this cellular component is added to the stem cell product to enrich it for regulatory T cells, which will modulate graft-versus-host disease.

References

1. Orca Bio announces FDA acceptance and priority review of the biologics license application (BLA) for Orca-T to treat hematological malignancies. News release. Orca Bio. October 6, 2025. Accessed April 9, 2026. https://tinyurl.com/urwb7244
2. Orca Bio announces FDA review extension of BLA for Orca-T for the treatment of hematologic malignancies. News release. Orca Bio. April 1, 2026. Accessed April 9, 2026. https://tinyurl.com/5atyjxbz